Janssen’s Rybrevant yields positive data
Results from trial showed a long-term response among specific lung cancer population
Read More
Tag: Rybrevant
FDA approves Janssen’s Rybrevant
First targeted treatment authorised in the US for NSCLC patients with EGFR exon 20 insertion mutations
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
